drugset / Trial / NCT04982939
Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate efficacy and safety of peri-operative sintilimab in combination with SOX in resectable locally advanced gastric or gastroesophageal junction adenocarcinoma
Timeline
- Start
- 2021-06-21
- Primary completion
- 2023-06-21
- Completion
- 2024-06-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Oxaliplatin | Small molecule | 130 mg/m2 | — |
| Background | S-1 | Small molecule | 40 mg | — |
| Background | S-1 | Small molecule | 60 mg | — |